Pfizer (PFE)
(Delayed Data from NYSE)
$29.09 USD
+0.12 (0.41%)
Updated Sep 27, 2024 04:02 PM ET
After-Market: $29.09 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.09 USD
+0.12 (0.41%)
Updated Sep 27, 2024 04:02 PM ET
After-Market: $29.09 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
Zacks News
Glaxo's (GSK) RSV Vaccine for Pregnant Women Enters Phase III
by Zacks Equity Research
Glaxo (GSK) is developing vaccine against respiratory syncytial virus for pediatric patients, pregnant women and older adults. The candidates hold significant potential.
3 Coronavirus Vaccine Makers Near Finish Line in November
by Zacks Equity Research
Positive developments related to coronavirus vaccine candidates have supported stock markets in November. Three leading coronavirus vaccine candidates achieve encouraging efficacy rate.
Celebrate Thanksgiving Week With These ETFs
by Sweta Killa
Thanksgiving week is here and history shows that this holiday-shortened week is a bullish feast for stock investors.
5 Top-Performing Leveraged ETF Areas of Last Week
by Sanghamitra Saha
Last week for Wall Street was all about vaccine optimism marred somewhat by rising virus cases and fears of further lockdowns.
Matador Resources (MTDR) Up 50.4% MTD: What's Driving It?
by Zacks Equity Research
Improving oil prices on encouraging coronavirus vaccine news aid Matador Resources (MTDR).
Cyclical Stocks Pop on Vaccine Progress: 5 Solid Buys
by Tirthankar Chakraborty
Positive news on the COVID-19 vaccine front revitalized the U.S. economy and vis-a-vis cyclical stocks like General Motors (GM), Delta Apparel (DLA) and Deere (DE).
5 Top-Performing ETFs of Last Week
by Sanghamitra Saha
Last week for Wall Street was all about vaccine optimism marred somewhat by rising virus cases and fears of further lockdowns.
Merck (MRK) to Buy OncoImmune, Add Late-Stage COVID-19 Treatment
by Zacks Equity Research
The acquisition of OncoImmune will boost Merck's (MRK) portfolio with CD24Fc, a candidate in phase III studies for the treatment of patients with severe and critical COVID-19.
Pfizer/BioNTech Seek Nod for Emergency Use of COVID-19 Vaccine
by Zacks Equity Research
Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine candidate is 95% effective in final analysis.
4 Sectors to Prosper in Thanksgiving Week
by Sanghamitra Saha
Back-to-back positive vaccine updates have offered sweet surprises to Wall Street from the start of the Thanksgiving month this year.
Markets Up on Sunny Holiday Outlook
by Mark Vickery
The NRF announced it expects U.S. holiday shopping season to grow 5.2% year over year, based on pent-up demand and higher U.S. savings rates during the pandemic.
AstraZeneca-Oxford Vaccine at 70% Efficacy
by Mark Vickery
One very positive piece of news from the AZN-Oxford study is that the doses may be refrigerated at normal cooler temperatures.
Gilead (GILD) Down on COVID-19 Drug Remdesivir Update
by Zacks Equity Research
Gilead's (GILD) remdesivir should not be used for hospitalized COVID-19 patients, as per the WHO's conditional recommendation.
Lilly/Incyte's Olumiant Gets FDA Emergency Nod for COVID-19
by Zacks Equity Research
Lilly's (LLY) rheumatoid arthritis drug, Olumiant gets Emergency Use Authorization for treating hospitalized COVID-19 patients in combination with Gilead's Veklury.
Stock Market News for Nov 20, 2020
by Zacks Equity Research
U.S. stock markets closed higher on Thursday on hopes of restarting of Congressional negotiations for a fresh tranche of fiscal stimulus.
Pharma Stock Roundup: PFE COVID-19 Vaccine Final Analysis, FDA Updates & More
by Kinjel Shah
Pfizer (PFE) COVID-19 vaccine candidate proves to be 95% effective in final analysis. Sanofi (SNY), Lilly (LLY), Merck (MRK) & Glaxo (GSK) provide FDA updates.
EOG Resources (EOG) Up 32.8% MTD: What's Behind the Rally?
by Zacks Equity Research
Improving oil prices on positive coronavirus vaccine results aid EOG Resources (EOG).
5 Top Stocks to Buy Amid Potential Economic Recovery
by Zacks Equity Research
With the U.S. economy showing steady signs of a recovery and promising vaccine trials, it will be prudent to invest in fundamentally sound stocks like Crocs (CROX) and FedEx (FDX).
Small Caps at the Forefront of Market Rally: 5 ETF Winners
by Sweta Killa
While the rally has been broad-based across all the market caps, small-caps stocks, as indicated by the Russell 2000 Index, has been outperforming and is hitting new all-time highs.
VBI Vaccines' (VBIV) Early Data on HBV Candidate Positive
by Zacks Equity Research
VBI Vaccines' (VBIV) early-stage hepatitis B virus immunotherapeutic candidate, VBI-2601, achieves promising immune response in patients on interim analysis.
Pfizer/BioNTech COVID-19 Vaccine Shows Final Efficacy of 95%
by Zacks Equity Research
Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine candidate proves to be 95% effective in final analysis.
Major Indices Fall Despite Positive Coronavirus Vaccine Data
by Indrajit Bandyopadhyay
Stock market declines as Pfizer (PFE) /BioNtech's (BNTX) vaccine candidate, with efficacy rate of 95%, gets overshadowed by fresh coronavirus cases and no sign of new fiscal stimulus.
Stock Market News for Nov 19, 2020
by Zacks Equity Research
Wall Street closed sharply lower on Wednesday on renewed threat of the latest surge in coronavirus infections.
What Awaits Pharma Giants in Last Lap of COVID-19 Vaccine Race?
by Ritujay Ghosh
Pfizer, Inc. (PFE), BioNTech SE (BNTX), Eli Lilly and Company (LLY), AstraZeneca plc (AZN), Moderna, Inc. (MRNA) and Gilead Sciences, Inc. (GILD) are leading the race to come up with a vaccine for coronavirus.
U.S. Crude Hits its Highest Price in 2 Months: Here's Why
by Nilanjan Choudhury
Some of the top gainers of the S&P 500 during the past month include energy-related names like Devon Energy (DVN), Baker Hughes Company (BKR), Diamondback Energy (FANG) and Marathon Oil (MRO).